Moving gut microbiome research from association to causality in cardiometabolic disease
The Novo Nordisk Foundation Microbiome Health Initiative is a virtual research centre translating gut microbiome discoveries into new strategies for prevention and treatment of cardiometabolic disease in humans.
Our mission is to move microbiome research from association to causality
The Novo Nordisk Foundation Microbiome Health Initiative, or MHI, was created to accelerate the development of microbiome-based solutions for cardiometabolic disease, or CMD.
In practice, that means uncovering how gut microbial functions and metabolites directly influence disease; connecting mechanistic research with preclinical and clinical studies; and translating discovery into strategies that can improve prevention and treatment of CMD.
In practice, that means uncovering how gut microbial functions and metabolites directly influence disease; connecting mechanistic research with preclinical and clinical studies; and translating discovery into strategies that can improve prevention and treatment of CMD.
Who we are
Our work draws on the collective experience and knowledge of MHI’s academic and clinical partners in a coordinated international research effort supported by the Novo Nordisk Foundation.
About us
The Latest from MHI
Oops, this feature requires cookies
To view the content, you must change your cookie consent to allow functionality cookies
Partners
Grant
The Novo Nordisk Foundation Microbiome Health Initiative (MHI) is supported by a Novo Nordisk Foundation grant number NNF24SA0092455.